Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters











Database
Language
Publication year range
1.
Drug Dev Res ; 80(8): 1110-1119, 2019 12.
Article in English | MEDLINE | ID: mdl-31482584

ABSTRACT

We investigated whether clavulanic acid could improve learning and memory, in rats underwent bilateral occlusion of common carotid artery (2VO). Seventy male Wistar rats were subjected to 2VO, with a 1-week interval between right and left artery occlusions. After 2VO, animals received clavulanic acid (10, 20, 40 mg/kg, intraperitoneally), from day 8 to 20. Spatial memory was assessed in the Morris water maze, 1 week after the induction of 2VO (day 15). The mRNA expression levels of bcl-2, bcl2-associated x protein (bax), caspase-3, inducible nitric oxide synthase (iNOS), and amyloid beta precursor protein (APP) were measured in the neocortex and hippocampus. Clavulanic acid significantly decreased the escape latency and swimming time in the training trial days. As well, it increased time and distance percentage in the target quadrant, while it decreased such factors in the opposite quadrant in the final trial day, compared to 2VO + normal saline animals. Real time-PCR data showed a significant higher mRNA expression of bax, caspase 3, and iNOS in the hippocampus and neocortex of 2VO animal compared to nonoccluded rats. APP increased in the neocortex but not hippocampus. Compared with 2VO animals, clavulanic acid significantly down-regulated the expression of iNOS, caspase 3, and APP, accompanied by diminishing the bax/bcl2 ratio. Our results reveal a potential therapeutic use of clavulanic acid for cognitive dysfunction associated with cerebral hypoperfusion in vascular dementia and Alzheimer disease.


Subject(s)
Arterial Occlusive Diseases/etiology , Carotid Artery, Common , Clavulanic Acid/administration & dosage , Dementia, Vascular/drug therapy , Neuroprotective Agents/administration & dosage , Animals , Arterial Occlusive Diseases/complications , Caspase 3/genetics , Clavulanic Acid/pharmacology , Dementia, Vascular/etiology , Disease Models, Animal , Gene Expression Regulation/drug effects , Hippocampus/drug effects , Hippocampus/metabolism , Male , Neocortex/drug effects , Neocortex/metabolism , Neuroprotective Agents/pharmacology , Nitric Oxide Synthase Type II/genetics , Rats , Rats, Wistar , Spatial Memory/drug effects , bcl-2-Associated X Protein/genetics
2.
Brain Res ; 1720: 146238, 2019 10 01.
Article in English | MEDLINE | ID: mdl-31047885

ABSTRACT

BACKGROUND: This study aimed to investigate the antinociceptive effect of allopurinol, a xanthine oxidase inhibitor, in the chronic constriction injury (CCI) to sciatic nerve rat model of neuropathic pain. METHODS: Allopurinol administration (30, 60, 90 mg/kg, i.p.) was started at the time of nerve injury, and given for 14 continuous days. Behavioural tests (von Frey filaments, acetone drop, hot plate) were conducted on days 0, 3, 7, 10 and 14. Reverse transcriptase polymerase chain reaction (RT-PCR) analysis was performed on the spinal cord of CCI animals on day 14. The contribution of adenosine (A) receptors was tested using the methylxanthine theophylline, a non-selective A receptor antagonist and 1,3-dipropyl-8-cyclopentylxanthine (DPCPX), a selective A1 receptor antagonist, administered 30 min before allopurinol on day 10. RESULTS: CCI of the sciatic nerve resulted in a persistent mechanical allodynia, cold allodynia, and heat hyperalgesia, together with increased iNOS, bax/bcl2, iba-1 and TNF-α expression in the lumbar spinal cord of animals. The highest-dose group of allopurinol (90 mg/kg) attenuated pain-like behaviors compared with the normal saline treated group, and this was accompanied by normalization of iNOS, bax/bcl2, caspase 3, iba-1 and TNF-α gene expression changes. DPCPX and theophylline reversed the thermal anti-hyperalgesic effect of allopurinol. In contrast, the mechanical anti-allodynic effect was only prevented by theophylline. CONCLUSION: Allopurinol through interacting with different aspects of neuropathic pain, via anti-oxidant effects, protection against neuroinflammation, and activating adenosine receptors, could be useful in the treatment of patients with neuropathic pain.


Subject(s)
Allopurinol/pharmacology , Neuralgia/drug therapy , Neuralgia/metabolism , Allopurinol/metabolism , Animals , Hyperalgesia/metabolism , Male , Models, Animal , Neuralgia/physiopathology , Nociceptors/drug effects , Pain Measurement , Rats , Rats, Wistar , Sciatic Nerve/injuries , Spinal Cord/metabolism , Tumor Necrosis Factor-alpha/metabolism , Xanthines
3.
Life Sci ; 211: 252-260, 2018 Oct 15.
Article in English | MEDLINE | ID: mdl-30243647

ABSTRACT

AIM: Curcumin, derived from turmeric, has been demonstrated to be effective in controlling seizures, although the exact mechanism is yet unknown. In this study, the role of serotonin and its receptors in the anticonvulsant effect of curcumin was evaluated in mice. MAIN METHODS: Total 110 mice were randomly divided into 11 groups (n = 10). In the first to the fourth groups, the role of curcumin (150 mg/kg, i.p) and serotonin (PCPA (100 mg/kg); was used to deplete the brain serotonin levels) was investigated. The fifth group first received NAD-299 (4 mg/kg, sc), RS-102221 (5 mg/kg, i.p), SDZ205-557 Hydrochloride (1 mg/kg, i.p), and SB 26997 (10 mg/kg, i.p), then curcumin. The sixth group received NAD-299, curcumin. The animals in the seventh to ninth groups received 5-HT2C, 5-HT4, and 5-HT7 antagonists, respectively, with curcumin. The tenth group received HTR2C antagonist and the eleventh group received HTR4 antagonist. In all animals 25 min after curcumin PTZ (80 mg/kg; i.p) was injected. KEY FINDINGS: PCPA not only inhibited the anticonvulsant action of curcumin, but also reversed some of its anticonvulsant effect. The 5-HT1A, 5-HT2C and 5-HT4 antagonists diminished but 5-HT7 antagonist strengthened the anticonvulsant effect of curcumin. Evaluation of gene expression using real-time PCR confirmed that only 5-HT7 gene expression was reduced after curcumin injection. SIGNIFICANCE: According to these results, it may be suggested that curcumin exerts anticonvulsive effects by increasing the serotonin levels in the brain that influence receptors, including 5-HT1A, 5-HT2C, and 5-HT4 and likely through the reduction of 5-HT7 gene expression.


Subject(s)
Anticonvulsants/pharmacology , Curcumin/pharmacology , Pentylenetetrazole/toxicity , Seizures/drug therapy , Serotonin Receptor Agonists/pharmacology , Serotonin/pharmacology , Animals , Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Convulsants/toxicity , Drug Combinations , Male , Mice , Receptor, Serotonin, 5-HT1A/metabolism , Receptor, Serotonin, 5-HT2C/metabolism , Receptors, Serotonin/metabolism , Receptors, Serotonin, 5-HT4/metabolism , Seizures/chemically induced , Seizures/metabolism , Seizures/pathology
4.
Neurosci Lett ; 623: 13-21, 2016 06 03.
Article in English | MEDLINE | ID: mdl-27130820

ABSTRACT

Vascular dementia and Alzheimer disease are most common type of dementia. These diseases have been associated with cognitive decline and affected personal behavioral activities. Moreover, the pattern of cerebral blood flow in mild cognitive disorder has appeared as a predictive indication for the development into Alzheimer's disease. Permanent, bilateral occlusion of the common carotid arteries (2VO) is a standard animal model to study vascular dementia and chronic cerebral hypoperfusion. In present study neuroprotective and memory enhancing effects of auraptene (AUR), a citrus coumarin, were studied in 2VO rats. Different doses (25, 8 & 4mg/kg) of AUR were administered orally. The spatial memory performance was tested with Morris water maze after 2VO induction. Biochemical experiments and histopathological evaluations were also applied to investigate the neuroprotective effect of AUR in brain tissue. In comparison with 2VO group, AUR could significantly decrease the scape latency time in treated rats. Also AUR increased the percentage of time spent and traveled pathway in target quadrant on final trial test day. All behavioral results were confirmed by biochemical and histopathological data. Biochemical data indicated that AUR could decrease malondialdehyde (MDA), as lipid peroxidation indicator, and increase glutathione (GSH) content in cortex and hippocampus tissues. Histopathological data showed that AUR could protect cerebrocortical and hippocampus neurons against ischemia. This study demonstrated the memory enhancing effect and neuroprotective activity of AUR after induction of brain ischemia in a rat model of vascular dementia.


Subject(s)
Coumarins/therapeutic use , Dementia, Vascular/drug therapy , Neuroprotective Agents/therapeutic use , Nootropic Agents/therapeutic use , Animals , Cerebral Cortex/blood supply , Cerebral Cortex/metabolism , Cerebral Cortex/pathology , Dementia, Vascular/metabolism , Dementia, Vascular/pathology , Dementia, Vascular/psychology , Glutathione/metabolism , Hippocampus/blood supply , Hippocampus/metabolism , Hippocampus/pathology , Lipid Peroxidation , Male , Maze Learning/drug effects , Neurons/drug effects , Neurons/pathology , Rats, Wistar , Spatial Learning/drug effects , Spatial Memory/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL